Biotech | April 25, 2022
‘DREAM-ND’ and ‘DREAM-D’ Phase 3 trials of Desidustat published in American Journal of Nephrology
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Company has invested $150 million to build a 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina
Tc99m tilmanocept is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
Both companies have been selected for stand-by production by German government
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Exclusive distribution agreement brings Point-Of-Care (POC) haematology diagnostics to new regions in the Middle East
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
Technology Development Board supports commercialisation of Metal Injection Molding of implants
Subscribe To Our Newsletter & Stay Updated
